猪轮状病毒防控中治疗性抗体策略的研究与应用进展
猪轮状病毒(PoRV)致新生仔猪急性肠炎,无特异抗病毒治疗,疫苗交叉保护有限且抗原漂移致疫苗株与田间株不匹配。本文综述当前免疫预防局限,提出治疗性抗体补充策略,并总结抗体工程、体外重建与口服递送平台进展。
要点
- PoRV致新生仔猪呕吐、腹泻和脱水,常合并感染,经济损失大。
- 疫苗交叉保护有限,抗原漂移致疫苗株与田间株不匹配,母源抗体保护不足。
- 治疗性抗体可快速中和病毒、靶向特异,口服递送可模拟母源抗体自然获得途径。
核心结论
- 治疗性抗体可作为母源抗体的补充,用于PoRV早期干预和阻断病毒传播。
- 优化抗体工程和靶向递送系统对实现有效黏膜中和至关重要。
研究设计与样本
- 综述,总结当前PoRV免疫预防的主要局限,提出治疗性抗体补充策略,并概述抗体工程、体外重建和口服递送平台进展。
主要发现
- PoRV感染目前无特异性抗病毒治疗,疫苗仍是最具成本效益且广泛使用的控制措施。
- 仔猪早期保护依赖母源抗体(MADs),但PoRV基因型复杂且快速演变,交叉保护有限。
- 循环株抗原漂移常导致疫苗株与田间分离株不匹配,使仔猪无法获得足够有效的母源免疫。
- 治疗性抗体具有快速病毒中和、靶标特异性和即时保护效应。
- 口服给药可模拟母源抗体的自然获得途径,并直接在肠道黏膜发挥作用。
临床怎么用
- 在母源抗体保护不足时,可考虑治疗性抗体作为PoRV早期干预和阻断传播的补充策略。
- 应用时需关注抗体工程优化和口服靶向递送,以实现肠道黏膜有效中和。
局限性
- 本文为综述,未报告原始研究数据或定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rotavirus (RV) is one of the leading causes of acute viral gastroenteritis in young children and various neonatal animals worldwide, posing significant challenges to both public health and livestock production. Porcine rotavirus (PoRV) induces acute enteric infection in neonatal piglets, resulting in severe vomiting, diarrhea, and dehydration, and is frequently associated with co-infections that disrupt gastrointestinal function and cause huge economic losses. At present, no specific antiviral therapy is available for PoRV infection, and vaccination remains the most cost-effective and widely used control measure, with piglets relying on maternally derived antibodies (MADs) for early protection. However, the complex and rapidly evolving PoRV genotypes confer limited cross-protection, and antigenic drift of circulating strains often leads to mismatch between vaccine strains and field isolates, preventing piglets from acquiring sufficient and effective maternal immunity. Therapeutic antibodies, characterized by rapid virus neutralization, target specificity, and immediate protective effects, represent a promising supplement to maternal antibodies, particularly for early intervention and blocking viral transmission. Given that oral administration mirrors the natural acquisition route of maternal antibodies and enables direct action at the intestinal mucosa, optimizing antibody engineering and targeted delivery systems is crucial for achieving effective mucosal neutralization. This review summarizes the major limitations of current PoRV immunoprophylaxis, proposes therapeutic antibody supplementation strategies, and highlights advances in antibody engineering, in vitro reconstruction, and oral delivery platforms. These insights provide a theoretical foundation and technical roadmap for overcoming PoRV immunization bottlenecks and strengthening the prevention and control of diarrheal diseases in the swine industry.
引用
- Zheng S, Wang L, Xia X, et al. Advances in research and application of therapeutic antibody strategies for porcine rotavirus prevention and control. Vaccine. 2026. PMID: 42247746. doi:10.1016/j.vaccine.2026.128777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。